Pustular psoriasis is a rare and serious form of psoriasis that requires specialized medical attention and careful management to control symptoms, prevent complications, and improve patients’ daily lives.

Managing a Complex Skin Condition: What Treatment Can Achieve

Pustular psoriasis presents unique challenges for both patients and healthcare providers. While there is currently no cure for this condition, the primary goals of treatment focus on controlling the painful symptoms, reducing the frequency and severity of flare-ups, preventing serious complications, and helping patients maintain their quality of life. Treatment approaches must be tailored to each individual, taking into account whether the pustular psoriasis affects a small area of the body or spreads across larger regions.^[1]

The choice of treatment depends heavily on the type of pustular psoriasis a person has, the extent of skin involvement, and how the condition has responded to previous therapies. Healthcare providers follow established clinical guidelines developed by medical societies such as the National Psoriasis Foundation Medical Board, which provide evidence-based recommendations for managing different forms of this disease.^[12]

Today’s treatment landscape includes both standard therapies that have been used for years and innovative new approaches being tested in clinical trials. This combination offers hope to patients who may not have responded well to traditional treatments. Research into the underlying mechanisms of pustular psoriasis continues to advance, leading to the development of targeted therapies that address specific pathways involved in the disease process.^[11]

It’s important to understand that pustular psoriasis is a lifelong condition where symptoms may come and go throughout a person’s lifetime. However, with proper treatment, many patients can achieve significant improvement in their symptoms and reduce the inflammation that can lead to other health problems such as psoriatic arthritis, heart disease, and depression.^[1]

Standard Treatment Approaches for Pustular Psoriasis

The foundation of pustular psoriasis treatment consists of several categories of medications and therapeutic approaches that have been used successfully for many years. The selection of specific treatments depends on whether the condition is localized to small areas or affects larger portions of the body.

For localized forms of pustular psoriasis, particularly those affecting the hands and feet, topical treatments are often the first line of defense. These include corticosteroid creams and ointments that reduce inflammation and slow down the rapid skin cell growth characteristic of psoriasis. Topical corticosteroids come in various strengths, with milder formulations used for sensitive areas and stronger preparations reserved for tougher, less-sensitive skin. Other topical options include calcipotriene, a synthetic form of vitamin D that helps regulate skin cell production, and tacrolimus, an immunosuppressive agent that can be applied directly to affected areas.^[12]

When pustular psoriasis is more widespread or doesn’t respond adequately to topical treatments, systemic medications become necessary. These are drugs that work throughout the entire body rather than just on the skin surface. Oral retinoids, particularly acitretin and isotretinoin, are vitamin A derivatives that help normalize skin cell growth and reduce inflammation. These medications are considered first-line systemic therapies by medical experts.^[12]

Methotrexate is another important systemic treatment that works by suppressing the overactive immune system responsible for psoriasis symptoms. It has been used for decades to treat various forms of psoriasis and is taken as a weekly dose, either by mouth or by injection. Healthcare providers carefully monitor patients taking methotrexate through regular blood tests to ensure the medication isn’t affecting liver function or blood cell counts.^[12]

Cyclosporine is a powerful immunosuppressive medication that can provide rapid relief for severe pustular psoriasis. It works by dampening the immune system’s inflammatory response. Because of its potency and potential side effects, including impacts on kidney function and blood pressure, cyclosporine is typically used for shorter periods and requires close medical supervision.^[12]

Additional systemic options include hydroxyurea and 6-thioguanine, which have shown success in some patients. These medications work by interfering with DNA synthesis, thereby slowing the rapid cell division that occurs in psoriasis.^[12]

Biologic therapies represent a major advancement in pustular psoriasis treatment. These are medications made from living cells that target specific parts of the immune system involved in the disease process. Several biologics have shown effectiveness as second-line therapies for pustular psoriasis, including etanercept, adalimumab, ustekinumab, and secukinumab. These medications are typically given by injection or intravenous infusion and may be used when other treatments haven’t provided adequate relief.^[12]

For generalized pustular psoriasis specifically, infliximab has been recognized as a first-line treatment option. This biologic medication works by blocking tumor necrosis factor-alpha (TNF-alpha), a protein involved in inflammation. Infliximab is administered through intravenous infusion in a healthcare setting.^[12]

Phototherapy, also known as light therapy, involves exposing the skin to controlled amounts of ultraviolet light. This treatment can slow skin cell growth and reduce inflammation. However, it requires careful management, as too much ultraviolet light exposure can actually trigger pustular psoriasis flares in some individuals.^[1]

The duration of treatment varies considerably depending on the severity of the condition and how well a patient responds to therapy. Some people may need short-term treatment during flare-ups, while others require ongoing maintenance therapy to keep symptoms under control. Regular follow-up with healthcare providers is essential to monitor treatment effectiveness and adjust therapy as needed.^[1]

Side effects are an important consideration with any pustular psoriasis treatment. Topical corticosteroids, when used long-term or on large areas of skin, can cause skin thinning, stretch marks, and increased vulnerability to infections. Systemic medications may cause more widespread effects, including nausea, fatigue, increased infection risk, liver or kidney problems, and in the case of retinoids, birth defects if taken during pregnancy. Healthcare providers carefully weigh these risks against the benefits when recommending treatment plans.^[12]

Breakthrough Treatments in Clinical Trials

The landscape of pustular psoriasis treatment has been transformed by recent scientific discoveries about the disease’s underlying mechanisms. Research has revealed that genetic mutations in genes such as IL36RN (interleukin-36 receptor antagonist) play a crucial role in triggering the inflammatory cascade that leads to pustular psoriasis symptoms. This understanding has opened new avenues for developing highly targeted therapies.^[13]

The most significant recent breakthrough came in September 2022 when the United States Food and Drug Administration (FDA) approved spesolimab as the first-ever treatment specifically for generalized pustular psoriasis flares. This represented a historic milestone, as no therapy had previously been approved specifically for this rare and potentially life-threatening condition. Spesolimab is an interleukin-36 receptor antagonist, meaning it blocks the action of IL-36, a protein that drives the inflammation and rapid pustule formation characteristic of generalized pustular psoriasis.^[12]

The approval of spesolimab was based on results from the Effisayil 1 Trial, a Phase II clinical study that evaluated 53 adults experiencing generalized pustular psoriasis flares. In this trial, researchers used a scoring system called the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) to measure pustule formation and overall disease severity. After one week of treatment, 54% of patients who received spesolimab had complete clearing of pustules (a GPPGA pustulation score of zero), compared to only 6% of patients who received a placebo. Additionally, 43% of spesolimab-treated patients achieved an overall GPPGA score of zero or one, indicating clear or nearly clear skin, compared to just 11% in the placebo group.^[12]

The success of spesolimab led to an expanded approval in March 2024. The FDA extended the indication to include not only treatment of acute flares but also prevention of flares in adults and pediatric patients aged 12 years and older weighing at least 40 kilograms. This expanded approval was supported by results from the Effisayil 2 trial, a 48-week Phase III clinical study involving 123 patients. In this longer-term study, patients receiving spesolimab experienced an impressive 84% reduction in flare occurrence compared to those receiving placebo, demonstrating the medication’s effectiveness in preventing disease flares over time.^[12]

Spesolimab is administered by intravenous infusion, typically in a hospital or clinic setting, particularly during acute flares when patients may be experiencing severe symptoms and systemic illness. The medication works rapidly to interrupt the inflammatory cascade, potentially preventing the dangerous complications that can accompany severe generalized pustular psoriasis flares.^[8]

Beyond spesolimab, researchers are exploring other medications that target the interleukin-36 pathway. Case reports have documented success with anakinra, an IL-1 receptor antagonist originally developed for rheumatoid arthritis. While anakinra blocks a different interleukin than spesolimab, the IL-1 and IL-36 pathways interact closely in the inflammatory process of pustular psoriasis. Clinical trials are currently underway to formally evaluate IL-1 receptor antagonists for pustular psoriasis treatment.^[12]

Another promising area of investigation involves bimekizumab, a medication that targets both IL-17A and IL-17F, two proteins involved in the inflammatory response. In a small case series, bimekizumab therapy resulted in improvement in symptoms for adults with palmoplantar pustular psoriasis, the localized form affecting hands and feet. This dual-target approach may offer advantages over medications that block only a single inflammatory pathway.^[12]

Clinical trials for pustular psoriasis typically follow a phased approach. Phase I trials focus primarily on safety, testing the medication in a small number of participants to identify potential side effects and determine appropriate dosing. Phase II trials expand to larger groups and begin evaluating whether the treatment is effective at improving pustular psoriasis symptoms. Phase III trials involve even larger patient populations and compare the new treatment directly with existing standard treatments or placebo to determine if it offers meaningful benefits.^[12]

Many clinical trials for pustular psoriasis are conducted at specialized medical centers in multiple countries, including locations in the United States, Europe, and other regions. Patient eligibility for these trials depends on several factors, including the specific type of pustular psoriasis, disease severity, previous treatments tried, and overall health status. Patients interested in participating in clinical trials should discuss this option with their dermatologist, who can help identify appropriate studies and provide referrals to participating research centers.^[12]

The mechanism of action for newer therapies represents a fundamental shift in how pustular psoriasis is treated. Rather than broadly suppressing the immune system or simply reducing symptoms, these targeted treatments address the specific molecular pathways that drive the disease. By blocking key inflammatory proteins like IL-36, IL-1, or IL-17, these medications can interrupt the disease process at its source, potentially offering more effective and specific treatment with fewer side effects than older, less-targeted approaches.^[11]

Preliminary results from ongoing trials continue to generate optimism. Researchers are reporting improvements in clinical parameters such as pustule counts, skin inflammation scores, and measures of patients’ quality of life. Many newer treatments also demonstrate positive safety profiles in early testing, though longer-term studies are needed to fully understand their safety and effectiveness over years of use.^[12]

Most Common Treatment Methods

• Topical Treatments
  • Corticosteroid creams and ointments of varying strengths applied directly to affected skin to reduce inflammation
  • Calcipotriene (synthetic vitamin D) to help regulate skin cell production
  • Tacrolimus, an immunosuppressive agent for localized areas
• Oral Systemic Medications
  • Acitretin and isotretinoin (retinoids) to normalize skin cell growth
  • Methotrexate to suppress overactive immune response
  • Cyclosporine for rapid control of severe disease
  • Hydroxyurea and 6-thioguanine as alternative systemic options
• Biologic Therapies
  • Infliximab (anti-TNF-alpha) for generalized pustular psoriasis
  • Etanercept, adalimumab for moderate to severe disease
  • Ustekinumab targeting IL-12 and IL-23 pathways
  • Secukinumab blocking IL-17A
  • Spesolimab (IL-36 receptor antagonist) specifically approved for generalized pustular psoriasis flares
• Phototherapy
  • Controlled ultraviolet light exposure to slow skin cell growth and reduce inflammation
  • Requires careful monitoring to avoid triggering flares
• Emerging Therapies in Clinical Trials
  • Anakinra (IL-1 receptor antagonist) showing promise in case reports
  • Bimekizumab targeting both IL-17A and IL-17F for palmoplantar pustular psoriasis
  • Additional IL-36 pathway inhibitors under investigation